Immunosuppressive drugs: The first 50 years and a glance forward

Immunopharmacology

Volumn 47, Issue 2-3, 2000, Pages 63-83

  Allison, Anthony C ^a  

^a 1060 E Meadow Circle   (United States)

Author keywords

Alkylating agents; Apoptosis; Immunosuppressives; Kinases; Phosphatases; Purines; Pyrimidines

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; BREQUINAR; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATASE; PHOSPHOTRANSFERASE; PURINE; PYRIMIDINE; RAPAMYCIN; TACROLIMUS;

APOPTOSIS; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0034098326     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00186-7     Document Type: Article

References (146)

1. Abraham R.T., Wiedderecht G.J. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:1996;483-510.
2. Alarcón G.S. Methotrexate in rheumatoid arthritis. A clinician's perspective. Immunopharmacology. 2000.
3. Allegra C.J., Hoeng K., Yeh G.C. Evidence for direct inhibition of de novo purine synthesis by methotrexate. J. Biol. Chem. 262:1987;13520-13526.
4. Allison A.C., Almquist S.J., Muller C.D., Eugui E.M. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant. Proc. 23(Suppl. 2):1991;10-14.
5. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000.
6. Amano Y., Lee S.W., Allison A.C. Inhibition by glucocorticoids of the formation of interleukin-1α, interleukin-1β and interleukin-6; mediation by decreased mRNA stability. Molec. Pharm. 43:1993;176-182.
7. Amemiya H., Itoh H. Mizoribine (Bredinin®): mode of action and effects on graft rejection. Thomson A.W., Starzl T.E. Immunosuppressive Drugs: Developments in Anti-rejection Therapy. 1993;161-176 Edward Arnold, Boston.
8. Assmann T., Homey B., Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology. 2000.
9. Barnes P.J. Inhaled glucocorticoids for asthma. N. Engl. J. Med. 322:1995;868-875.
10. Bartlett R.R. Immunopharmacological profile of HWA486, a novel isoxazol derivative: II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A. Int. J. Immunopharmacol. 8:1986;199-204.
11. Bartlett R.R., Anagnostopoulos H., Zieliwski T.et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin. Immunopathol. 14:1993;381-394.
12. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42:1991;1569-1575.
13. Bishop G.A., Sharland A.F., McCaughan G.W. High-dose/activation associated tolerance model for allografts: lessons from spontaneous tolerance for transplanted livers. Curr. Opin. Organ Transplant. 4:1999;58-69.
14. Bishop G.A., Sun J., De Cruz D.J.et al. Tolerance to liver allografts III donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues. J. Immunol. 156:1996;4925-4931.
15. Boehme S.A., Leonardo M.J. Propriocidal apoptosis of mature T-lymphocytes occurs at the S phase of the cell cycle. Eur. J. Immunol. 23:1993;1552-1560.
16. Border W.A., Noble N.A. TGF β in kidney fibrosis: a target for gene therapy. Kidney Int. 51:1997;1388-1396.
17. Borel J.F., Feurer C., Gubler H.V.et al. Biological effects of cyclosporin A: a new anti-lymphocytic agent. Agents Actions. 6:1976;468-475.
18. Boyle M.J., Cahan B.D. Immunosuppressive role of rapamycin in allograft rejection. Thomson A.W., Starzl T.G. Immunosuppressive Drugs. 1994;129-140 Edward Arnold, Boston.
19. Brattström C., Wilczek H., Tyden G.et al. Hyperlipidemia in renal transplant patients treated with sirolimus (rapamaycin). Transplantation. 65:1998;1272-1274.
20. Brinkmann V., Pinschewer D., Feng L. FTY720 suppresses immune responses by modulating G-protein coupled receptors on lymphocytes resulting in altered lymphocyte homing. Transplantation. 67:1999;S226.
21. Bryer H.P., Isserow J.A., Armstrong E.C.et al. Azathioprine alone is bone sparing and does not alter cyclosporin induced osteopenia in the rat. J. Bone Miner. Res. 10:1995;132-138.
22. Burke G.W., Giancio G., Alejandro R.et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK506 immunosuppression. Transplant. Proc. 30:1998;513-514.
23. Carlson R.P., Baeder W.L., Caccese R.G.et al. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann. N.Y. Acad. Sci. 685:1993;86-113.
24. Chabner B.A., Allegra C.J., Curt G.A.et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76:1985;907-912.
25. Chabner B.A., Allegra C.J., Curt G.A., Calabresi P. Antineoplastic agents. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edn. 1996;1233-1287 McGraw-Hill, New York.
26. Chang G.L., Erdmann G.R., Gruber S.A.et al. Pharmacokinetics of 6-MP, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 30:1990;358-363.
27. Chang G., Wilensky R., Loh E.et al. Elevated triglyceride levels are associated with early endothelial dysfunction (ED) after heart transplantation (HT). Transplantation. 67:1999;S103.
28. Chen S.-F., Ruben R., Dexter D. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res. 46:1986;5014-5019.
29. Cherwinski H.M., Cohn R.G., Cheung P.et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275:1995;1043-1049.
30. Cohn R.G., Mirkovich A., Dunlap B.et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation. 68:1999;411-418.
31. Cohn R.G., Mirkovich A., Caulfield J.P., Eugui E.M. Apoptosis of human activated peripheral T-cells and T-lymphocytic and promonocytic cell lines induced by mycophenolic acid, the active metabolite of CellCept. The Sixth Basic Sciences Symposium of the Transplantation Society, Monterey, CA:1999;173. Abstracts.
32. Contreras J.L., Wang P.X., Eckhoff D.E.et al. Peritransplant tolerance induction with anti-CD3 immunotoxin: a matter of proinflammatory cytokine control. Transplantation. 65:1998;1159-1169.
33. Cordier G., Garnier H., Clot J.et al. La greffe de foie orthotopique chez le porc; premiers resultats. Mem. Acad. Chir. 92:1965;27-35.
34. Cramer D.V., Chapman F.A., Jaffeeet al. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation. 53:1992;303-308.
35. Curtis J.J., Luke R.G., Duborsky E.et al. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet. 2:1986;477-479.
36. Dai Z.H., Konieczny B.T., Baddoura F.K.et al. Impaired alloantigen-mediated T-cell apoptosis and failure to induce long-term allograft survival in IL-2 deficient mice. J. Immunol. 161:1998;1659-1663.
37. Dayton J.S., Turka L.A., Thompson C.B., Mitchell B.S. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine metabolism. Molec. Pharmacol. 41:1992;671-676.
38. Dempster D.W. Bone histomorphometry in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 4:1989;137-141.
39. de Haan A., Van den Berg A., van der Bij W.et al. Liver allografts, but not lung allografts, induce a decrease in donor-specific cytotoxic T-cell precursors in the early post-transplant period: correlation with freedom from chronic graft dysfunction. Sixth Basic Sciences Symposium of the Transplantation Society:1999;141.
40. Dissanayake I.R., Goodman G.R., Bowman A.R.et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation. 65:1998;275-278.
41. Dodge I.L., Li X.C., Strom T.B. Rapamycin induces TGF-β production in lymphocytes. Transplantation. 67:1999;S50.
42. Elion G.B. The purine path to chemotherapy. Science. 244:1989;41-47.
43. Epinette W.W., Parker C.M., Jones E.L., Greist M.C. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety. J. Am. Acad. Dermatol. 17:1987;962-967.
44. Farber S., Toch R., Manning Sears E., Pinkel D. Advances in chemotherapy of cancer in man. Greenstein H.A. Advances in Cancer Research. 1956;2-73 Academic Press, New York.
45. Franklin T.J., Cook J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 113:1969;515.
46. Friedman R.M., Buckler C.E., Baron S. The effect of aminomethylpteryl glutamic acid on the development of skin hypersensitivity and antibody formation in guinea pigs. J. Exp. Med. 114:1961;173-183.
47. Fuster V., Vorchheimm D.A. Prevention of atherosclerosis in coronary-artery bypass grafts. N. Engl. J. Med. 336:1997;212-213.
48. Genestier L., Paillot R., Fournel S.et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T-cells. J. Clin. Invest. 102:1998;322-328.
49. Genestier L., Paillot R., Quemenew L.et al. Mechanisms of action of methotrexate. Immunopharmacology. 2000.
50. Gilman A., Phillips F.S. The biological actions and therapeutic applications of β-chlorethylanines and sulfides. Science. 103:1946;409-415.
51. Gosio B. Richerche batteriologiche e chemiche sulle alterazoni dei Mais Riv. D'Igiene Sanita Pub. Ann. 7:1896;825-849.
52. Gregory C.R., Huie P., Shorthouse R.et al. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. Transplant. Proc. 25:1993;120-121.
53. Grimm P.C., Jeffery J., Niderson P.et al. In 6 month protocol renal transplant biopsies long-term allograft outcome is predicted by using the Banff score or quantitation of fibrosis using image analysis of Sirius red staining. Transplantation. 67:1999;S56.
54. Groth C.G., Bäckman L., Morales J.-M.et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation. 67:1999;1036-1042.
55. Hench P.S., Kendall E.C., Slocumb C.H., Polley H.F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, compound 8E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet Mayo Clin. 24:1949;181-197.
56. Herman W.H., Hircik D.E., Simonson M.S. Cyclosporine activates the endothelin converting enzyme: implications for acute and chronic nephrotoxicity. Transplantation. 67:1999;S52.
57. Herrmann M.L., Schleyerbach R., Kirschbaum B.J. Leflunomide: an immuno-modulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000.
58. Hojo M., Morimoto T., Maluccio M.et al. Cyclosporine induces cancer progression by a cell autonomous mechanism. Nature. 397:1999;530-534.
59. Hrelia P., Murelli L., Scotti M.et al. Organo-specific activation of azathioprine in mice: role of liver metabolism in mutation induction. Carcinogenesis. 9:1988;1011-1015.
60. Ichikawa N., Demetris A.J., Ye Q. Costimulatory molecule expression in heart allografts developing chronic rejection and tolerance. Sixth Basic Sciences Symposium of the Transplantation Society:1999;52.
61. Ismaili J., Tassignon J., Lemoine A.et al. Azodicarbonamide as a new immunosuppressive agent. Transplantation. 67:1989;S61.
62. Iwasawa H., Kondo S., Ikeda D.et al. Synthesis of (-)-15-deoxysperguelin and (-)-spergualin-15-phosphate. J. Antibiot. (Tokyo). 35:1982;1665-1669.
63. Iwata H., Wada Y., Walsh M.et al. In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor. Transplant. Proc. 30:1998;983-986.
64. Joffe I., Katz I., Jacobs T.et al. 17-β estradiol prevents osteopenia induced in the oophorectomized rat treated with cyclosporin A. Endocrinology. 130:1992;1578-1585.
65. Johnsson C., Tufveson G. MC1288 - a vitamin D analogue with immunosuppressive effects of heart and small bowel grafts. Transplant Int. 7:1994;392-397.
66. Jones J.W., Guo S., Su S., Fernandez R. Cyclosporine A stimulation of smooth muscle cell proliferation is associated with increased expression of 14-3-3γ protein. Transplantation. 67:1999;S65.
67. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology. 55:1985;369-389. (review article).
68. Kamada N., Teramoto K., Baguiero A.et al. Cellular basis of transplantation tolerance induced by liver grafting in rats. Extent of clonal deletion among thoracic duct lymphocytes, spleen and lymph node cells. Transplantation. 46:1988;165-167.
69. Kawabe Y., Ochi A. Programmed cell death and extrathymic reduction of Vβ8+CD4+ T-cells in mice tolerant to Staphyloccus aureus enterotixin B. Nature. 349:1991;245-248.
70. Khanna A. TGF-beta provides the rationale for the synergistic immunosuppression with rapamycin (RAPA), cyclosporine (CsA) and tacrolimus (TAC). Transplantation. 67:1999;S58.
71. Khanna A., Bresnahan B., Plummer M.et al. Intrarenal expression of fibrogenic genes in renal allografts with tacrolimus and cyclosporine nephrotoxicity. Transplantation. 67:1999;S84.
72. Khanna A., Vincent F. Intra-graft expression of fibrogenic genes is decreased in calcineurin inhibitors sparing immunosuppression protocol. Transplantation. 67:1999;S80.
73. Kieslow P., von Boehmer H. Development and selection of T-cells: facts and puzzles. Adv. Immunol. 58:1995;87-209.
74. Kino T., Hatanaka H., Miyata S.et al. FK506, a novel immunosuppressant isolated from a streptomyces: III. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo). 40:1987;1256-1265.
75. Kirk A.D., Burkly L.C., Patty D.S.et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (N.Y.). 5:1999;686-693.
76. Ko S., Deiwick A., Jäger M.D.et al. The functional relevance of passenger leukocytes and microchimerism for heart graft acceptance in the rat. Nat. Med. (N.Y.). 5:1999;1292-1297.
77. Kobayashi E., Kamada N., Delriviere L.et al. Migration of donor cells into the thymus is not essential for induction and maintenance of systemic tolerance after liver transplantation in the rat. Immunology. 84:1995;333-336.
78. Kroemer G. The pharmacology of T-cell apoptosis. Adv. Immunol. 58:1995;211-296.
79. Kronke M., Leonard W.J., Depper J.M.et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl. Acad. Sci. U.S.A. 81:1984;5214-5218.
80. Lehnert A.M., Yi S., Burgess J., O'Connell P.J. Increased T-cell apoptosis but not immune deviation is associated with tolerance following short term CTLA4-Fc and anti-CD40L mAb treatment. In The Sixth Basic Sciences Symposium of the Transplantation Society, Monterey, CA:1999;53.
81. Leonardo M.J. Interleukin-2 programs mouse alpha-beta T-lymphocytes for apoptosis. Nature. 353:1991;763-769.
82. Li B., Sehajpal P., Khanna A.et al. Differential regulation of transforming growth factor-β and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in quantitative polymerase chain reaction. J. Exp. Med. 174:1991;1259-1264.
83. Li Y., Li X.C., Zheng X.X.et al. Blocking signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T-cells and induction of peripheral tolerance. Nat. Med. (N.Y.). 5:1999;1298-1302.
84. Liu J., Farmer J.D., Lane W.S.et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
85. Makowka L., Cramer D.V. Brequinar sodium: mode of action and effects on graft rejection. Thomson A.W., Starzl T.E. Immunosuppressive Drugs: Developments in Anti-rejection Therapy. 1993;177-186 Edward Arnold, Boston.
86. Martel R.R., Klicius J., Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55:1977;48-51.
87. Massagúe J. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6:1990;597-641.
88. Mathew T.H. Tricontinental mycophenolate mofetil renal transplantation study group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in renal transplantation. Results at three years. Transplantation. 65:1999;1450-1454.
89. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000.
90. Meyer D., Thorwath M., Otto C.et al. Apoptosis of alloreactive T-cells in liver grafts during tolerance induction. Transplant. Proc. 31:1999;474.
91. Mihatsch M.J., Morozumi K., Strom E.H.et al. Renal transplant morphology after long-term therapy with cyclosporine. Transplant. Proc. 27:1995;39-42.
92. Morabito L., Mortesino M.C., Schreibman D.M.et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires 5′-ectonucleotidase conversion of adenine nucleotides. J. Clin. Invest. 101:1998;295-300.
93. Morris R.E., Meiser B.M., Wu T.et al. Use of rapamycin for the suppression of alloimmune reactions in vivo-schedule dependence, tolerance induction, and synergy with cyclosporine and FK-506 and effect on host-versus-graft and graft-versus-host reactions. Transplant. Proc. 23:1991;521-524.
94. Morrisett J.D., Ballantyne C.M., Pownall H.J.et al. Effect of sirolimus on plasma lipid and lipoprotein levels and metabolism in renal transplant recipients. Transplantation. 67:1999;S60.
95. Murray J.E., Merrill J.P., Harrison J.H.et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N. Engl. J. Med. 268:1963;1315-1323.
96. Naimark D.M.J., Cole E. Determinants of long-term allograft survival. Transplant. Rev. 8:1994;931.
97. Ochiai T., Nakajima K., Nagata M.et al. New immunosuppressive drugs. Effect of a new immunosuppressive agent, FK-506, on heterotopic cardiac allotransplantation in the rat. Transplant. Proc. 19:1987;1284-1286.
98. Okubo M., Kamata K., Yakota K.et al. Effect of Bredinin on cellular and humoral immune responses and on canine kidney allograft survival. Transplant. Proc. 12:1980;515-519.
99. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative transplant study. Transplantation. 60:1995;1220-1224.
100. Pardo-Mindán F.J., Errasti P., Panizo A.et al. Decreased apoptosis rate in patients treated with mycophenolate mofetil. Nephron. 82:1996;232-237.
101. Pedersen T.R., Kjekshus J., Berg K.et al. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (45). Lancet. 349:1994;1383-1389.
102. Qian S., Lu L., Fu F.et al. Apoptosis within spontaneously accepted mouse liver-allografts. Evidence for deletion of cytotoxic T-cells and implications for tolerance induction. J. Immunol. 158:1997;4654-4661.
103. Räisänen-Sokolowski A., Pakkala I., Vuoristo P.et al. Effect of MC1288, a vitamin D analogue, on lymphocyte proliferation and rat aortic allograft arteriosclerosis in vivo. Transplant. Proc. 28:1996;919.
104. Ranich T., Li B., Sharma U.K.et al. Transforming growth factor-β1 inducible gene-h3 (βig-h3) mRNA expression correlates with TGF-β1 mRNA hyperexpression in human renal allografts. Transplantation. 67:1999;S251.
105. Rollinghoff M., Starzinski-Powitz A., Pfizenmaier K., Wagner H. Cyclophosphamide-sensitive T-lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T-lymphocytes. J. Exp. Med. 145:1977;455-459.
106. Sadlack B., Merz H., Schorle H.et al. Ulcerative colitis-like disease in mice with disrupted IL-2 gene. Cell. 75:1993;253-261.
107. Sakaguchi K., Tsiyino M., Yoshizaroa M.et al. Action of bredinin on mammalian cells. Cancer Res. 35:1975;1643-1648.
108. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am. J. Gastroenterol. 91:1996;423-433.
109. Sanders C.F.J., Curtis J.J. Role of hypertension in chronic allograft dysfunction. Kidney Int. 48:1995;S431.
110. Santos G., Owens A.H. Jr., Sensenbrenner L.L. Effect of selected agents on antibody production in man: a preliminary report. Am. N.Y. Acad. Sci. 114:1964;404-423.
111. Schorlemmer H.U., Milbert U., Schleyerbach R., Kirchbaum R. Malononitrilamides (MNAs) exert their immunosuppressive activity primarily by inhibition of dihydroorotate dehydrogenase (DHOH). Transplantation. 67:1999;S60.
112. Schwartz R., Dameshek W. Drug-induced immunological tolerance. Nature. 183:1959;1682-1683.
113. Schwartz R., Dameshek W. The effects of 6-mercaptopurine on homograft reactions. J. Clin. Invest. 39:1960;952-958.
114. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY-22,989), a new fungal antibiotic: 11. Fermentation, isolation and characterization. J. Antibiot. 38:1975;727-732.
115. Sharland A., Yau Y., Wang C.et al. Evidence that apoptosis of activated T-cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations that break tolerance. Transplantation. 1999;. (in press).
116. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 33:1995;1301-1305.
117. Shihab F., Andoh T., Tamer A., Bennett W. The expression of pro-apoptotic genes is favored in chronic cyclosporine nephrotoxicity. Transplantation. 67:1999;S214.
118. Shimizu Y., Goto S., Varí F.et al. Restoration of tolerance to rat hepatic allografts by spleen-derived passenger leukocytes. Transplant. Int. 6:1996;593-595.
119. Simonson M., Robinson A., Herman W.et al. Endothelin-1 mediates transplant vasculopathy and chronic rejection in LEW/F344 cardiac allografts. Transplantation. 67:1999;S52.
120. Sintchak M.D., Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology. 2000.
121. Smith C., Shimizu Y., Otomo N.et al. Cyclosporine administration prevents intrathymic (IT) tolerance induction and precipitates rejection of established IT tolerant rat cardiac allografts. Sixth Basic Sciences Symposium of the Transplantation Society, Monterey, CA:1999;178.
122. Song H., Seta K., Kinjo P.et al. Decreasing expression of transforming growth factor-beta in human renal biopsies with improvement of renal pathological score and renal function following chronic cyclosporine reduction. Transplantation. 67:1999;S236.
123. Stender H.S., Ringleb D., Strauch D., Winter H. Die Beinflussing der Antikörper-bildung durch Zytostatika and Rontgenbestrahling. Strahlentherapie. 43:1959;392-399.
124. Sun J., Shiel A.G.R., Wang C.et al. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes. Transplantation. 62:1996;1725-1730.
125. Suzuki S. Deoxyspergualin: mode of action and effects on graft rejection. Thomson A.W., Starzl T.E. Immunosuppressive Drugs: Developments in Anti-rejection Therapy. 1994;187-202 Edward Arnold, Boston.
126. Suzuki H., Kumdig T.M., Furlonger C.et al. Deregulated T-cell activation and autoimmunity in mice lacking interleukin-2 receptor. Science. 268:1995;1472-1476.
127. Sykes M. Chimerism and central tolerance. Curr. Opin. Immunol. 81:1996;694-703.
128. Sytwu H.K., Lieblau R.S., McDevitt H.O. The roles of Fas/Apo 1 (CD95) and TNF in antigen-induced programmed cell death in T-cell receptor transgenic mice. Immunity. 5:1996;17-30.
129. Takahashi T., Tanaka M., Brannan C.I.et al. Generalized lymphoproliferative disease caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
130. Takeuchi T., Iinuma H., Kunimoto S. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J. Antibiot. (Tokyo). 34:1981;1619-1621.
131. Thiebaud D., Krieg M.A., Gillard-Berguer D.et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. J. Clin. Invest. 26:1996;549.
132. Tsui T.Y., Schlitt H.J. Induction of long-term allograft survival by post-transplant infusion of allogeneic leukocytes and delayed low-dose cyclosporine. The Sixth Basic Sciences Symposium of the Transplantation Society. 1999;203. Abstracts.
133. Turk J.L. Studies on the mechanism of action of methotrexate and cyclophosphamide on contact sensitivity in the guinea pig. Int. Arch. Allergy. 24:1964;191-200.
134. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:1998;243-248.
135. Viklicky V., Hubacek J.A., Loche J.et al. Long-term renal graft survival and ACE gene polymorphism. The Sixth Basic Sciences Symposium of the Transplantation Society. 1999;186. Abstracts.
136. Waer M. The use of leflunomide in transplantation immunology. Transplant Immunol. 4:1996;181-185.
137. Watanabe-Fukunagas R., Brannan C.I., Copland N.G.et al. Lymphoproliferation disorder explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
138. Webb S., Morris C., Sprent J. Extrathymic tolerance of mature T-cells: clonal elimination as a consequence of immunity. Cell. 63:1990;1249-1256.
139. Wei C., Song H., Seta K.et al. Chronic cyclosporine reduction decreases apoptosis and p53 expression in human renal biopsies with improvement of renal pathological score and renal function. Transplantation. 67:1999;S51.
140. Wolberg G. Antipurines and purine metabolism. Handb. Exp. Pharmacol. 85:1988;517-530.
141. Wells A.D., Li X.C., Li Y.et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. (N.Y.). 5:1999;1303-1307.
142. Xiao F., Chang A.S.-F., Bartlett R.R., Williams J.W. Leflunomide: a promising immunosuppressant in transplantation. Thomson A.W., Starzl T.E. Immunosuppressive Drugs: Developments in Anti-rejection Therapy. 1994;203-212 Edward Arnold, Boston.
143. Yamashita K., Nomura M., Takehara M.et al. Effects of a novel immunosuppressant, FTY720, on heart and liver transplantation. Transplantation. 1999;S226.
144. Zheng L., Fisher G., Miller R.E.et al. Induction of apoptosis in mature T-cells by tumor necrosis factor. Nature. 377:1995;348-351.
145. Zhou T., Song L., Yang P.et al. Bisindolylamide VIV facilitates Fas-mediated apoptosis and inhibits T-cell-mediated autoimmune diseases. Nat. Med. (N.Y.). 5:1999;42-48.
146. Zimmermann F.A., Davies H.S., Knoll P.P.et al. Orthotopic liver allografts in the rat: influence of strain combination on the fate of the graft. Transplantation. 37:1984;406-410.